UCB, a Belgian pharmaceutical company, has been investigated by industry and commerce to fight bribery or expand its scope

UCB, a Belgian drugmaker, said Thursday that its Shanghai office had been investigated by the Chinese industry and Commerce Department in the past 48 hours "Officials from the China Administration for Industry and Commerce have visited us," a company spokesman said "They have launched an investigation into several pharmaceutical companies active in this country, including both Chinese companies and foreign companies like us." The spokesman added that the purpose of the visit to UCB's Shanghai office was to seek compliance information According to Reuters, UCB, a Belgian pharmaceutical company, was investigated by Chinese industry and commerce, marking the expansion of the investigation into bribery in the pharmaceutical industry after GlaxoSmithKline in the UK Chinese police have previously accused GlaxoSmithKline of offering bribes to Chinese officials and doctors to boost sales, as well as raising the price of drugs, showing a strong stance against the improper conduct of multinational companies operating in China Previously, there were rumors that the Shanghai Office of youshibi, Abbott, Roche, Novartis and other corporate offices were visited by relevant departments Youshibi once declined to comment on this; Roche said that the company had not received the government's notice on its anti-corruption investigation; Novartis said in its statement that the Chinese government departments had not contacted the company about anti-corruption, Novartis had not received the relevant investigation, while the Wuhan Office as mentioned by the outside world had not been investigated by any government departments in fact; Abbott said The matter was denied China's State Administration for Industry and commerce is one of the three antitrust regulators in charge of market supervision The agency's investigation activities often overlap those of the national development and Reform Commission, the top regulator, which recently launched a price manipulation investigation of domestic and international pharmaceutical giants, including GlaxoSmithKline, Merck and anstelai Company profile: UCB, founded in 1928, is headquartered in Brussels, Belgium, with three R & D centers in slough, London and Cambridge, UK Ushibi pharmaceutical in China includes ushibi Trading (Shanghai) Co., Ltd and Zhuhai Schwarz Pharmaceutical Co., Ltd., with businesses all over the country Its products involve central nervous system diseases, allergic diseases, cardiovascular diseases, anemia and pain treatment, etc Youshibi pharmaceutical has a global presence in more than 40 countries, with more than 10000 employees In 2008, the global sales revenue was 3.6 billion euros The world's top 100 pharmaceutical industry ranks 27th With the continuous expansion of business, in May 2004, ushibi pharmaceutical completed the acquisition of cell technology, a British biopharmaceutical enterprise On September 1, 2007, the global acquisition of Schwarz Pharmaceutical Group was completed So far, ushibi pharmaceutical company has successfully realized the strategic positioning of the world's leading biopharmaceutical company.